Rule 3.19A.2

## **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/2011

Name of entity	SIGMA PHARMACEUTICALS LIMITED	
ABN	ABN 15 088 417 403	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Gerald MANUEL
Date of last notice	07/04/2011

## Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	11/04/2011
No. of securities held prior to change	58,261
Class	FPO
Number acquired	6,349
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$3,125.00
No. of securities held after change	64,610
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares purchased under Sigma's customer loyalty Embrace Equity Plan.

<sup>+</sup> See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

**Detail of contract** 

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to	
which interest related prior to	
change	
Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	
Part 3 – <sup>+</sup> Closed period	
Were the interests in the	No
securities or contracts detailed	
above traded during a <sup>+</sup> closed	
period where prior written clearance was required?	
If so, was prior written clearance	
provided to allow the trade to proceed during this period?	

provided?

If prior written clearance was provided, on what date was this

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.